Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy

AIDS

Volumn 20, Issue 8, 2006, Pages 1171-1179

  Sullivan, Patrick S ^a,c   Hanson, Debra L ^a   Teshale, Eyasu H ^a   Wotring, Linda L ^b   Brooks, John T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HAART; Hepatitis C; HIV; Survival

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEPATITIS; ADOLESCENT; ADULT; ALCOHOLISM; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC HEPATITIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; MATHEMATICAL ANALYSIS; MEDICAL RECORD; MORTALITY; OUTPATIENT DEPARTMENT; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TOXIC HEPATITIS; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALCOHOLISM; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HEPATITIS B; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 33646870819     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000226958.87471.48     Document Type: Article

References (46)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
2. Borgia G, Reynaud L, Gentile I, Piazza M. HIV and hepatitis C virus: facts and controversies. Infection 2003; 31:232-240.
3. Telfer PT, Brown D, Devereux H, Lee CA, DuSheiko GM. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994; 88:397-399.
4. Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28:945-950.
5. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14:949-953.
6. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
7. Graham CS, Baden LR, Yu E, Mrus JM, Garnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
8. Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:1293-1297.
9. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
10. Haydon GH, Flegg PJ, Blair CS, Brettle RP, Burns SM, Hayes PC. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Castroenterol Hepatol 1998; 10:485-489.
11. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-249.
12. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998; 12:381-388.
13. Piroth L, Grappin M, Cuzin L, Mouton Y, Bouchard O, Raffi F, et al. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J Viral Hepat 2000; 7:302-308.
14. Voirin N, Trepo C, Miailhes P, Touraine JL, Chidiac C, Peyramond D, et al. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database. J Viral Hepat 2004; 11:559-562.
15. Carlos MJ, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004; 5:125-131.
16. El-Serag HB, Giordano TP, Kramer J, Richardson P, Souchek J. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Castroenterol Hepatol 2005; 3:175-183.
17. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39:1507-1513.
18. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18:2039-2045.
19. Daar ES, Lynn H, Donfield S, Gomperts E, O'Brien SJ, Hilgartner MW, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589-595.
20. De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162:2125-2132.
21. Dorrucci M, Valdarchi C, Suligoi B, Zaccarelli M, Sinicco A, Giuliani M, et al. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS 2004; 19;18:2313-2318.
22. Rancinan C, Neau D, Saves M, Lawson-Ayayi S, Bonnet F, Mercie P, et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002; 16:1357-1362.
23. Rezza G. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17 (Suppl. 1 ):S13-S16.
24. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
25. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41:713-720.
26. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002.
27. Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 39:613-619.
28. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005; 41:906-911.
29. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5:174-179.
30. Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis coinfection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169-1177.
31. Mayor AM, Gomez MA, Fernandez DM, Rios-Olivares E, Thomas JC, Hunter RF. Morbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection. Am J Trop Med Hyg 2006; 74:239-245.
32. Farizo KM, Buehler JW, Chamberland ME, Whyte BM, Froelicher ES, Hopkins SG, et al. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA 1992; 267:1798-1805.
33. Collett D. Modeling survival data in medical research. London: Chapman and Hall; 1994.
34. Andersen PK, Gill RD. Cox's regression model counting process: a large sample study. Ann Stat 1982; 10:1100-1120.
35. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrics 1994; 81: 515-526.
36. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines/adult/ AA_040705.pdf. Last accessed: 21 September 2005.
37. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
38. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
39. van AL, Prins M. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression. AIDS 2004; 18:2319-2324.
40. Sabin CA, Teller P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175:164-168.
41. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
42. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6:99-106.
43. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
44. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
45. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HlV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. lnt J Epidemiol 2005; 34:121-130.
46. United States Public Health Service. Recommendations to help patients avoid exposure to or infection from opportunistic pathogens. Available at: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr5108a2.htm. Last accessed: 20 September 2005.